Sarah Burdett
Overview
Explore the profile of Sarah Burdett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
4840
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vale C, Fisher D, Godolphin P, Rydzewska L, Boher J, Burdett S, et al.
Lancet Oncol
. 2023 Jul;
24(7):783-797.
PMID: 37414011
Background: Adding docetaxel to androgen deprivation therapy (ADT) improves survival in patients with metastatic, hormone-sensitive prostate cancer, but uncertainty remains about who benefits most. We therefore aimed to obtain up-to-date...
2.
Xu Z, Ibrahim S, Burdett S, Rydzewska L, Al Wattar B, Davies M
Eur J Obstet Gynecol Reprod Biol
. 2022 Dec;
281:41-48.
PMID: 36535069
Objective: As cancer survivorship increases, there is higher uptake of fertility preservation treatments among affected women. However, there is limited evidence on the subsequent use of preserved material and pregnancy...
3.
Fisher D, Burdett S, Vale C, White I, Tierney J
Syst Rev
. 2022 Dec;
11(1):274.
PMID: 36527153
Background: Research overlap and duplication is a recognised problem in the context of both pairwise and network systematic reviews and meta-analyses. As a case study, we carried out a scoping...
4.
Hall H, Tocock A, Burdett S, Fisher D, Ricketts W, Robson J, et al.
Thorax
. 2021 Aug;
77(8):762-768.
PMID: 34404753
Background: National targets for timely diagnosis and management of a potential cancer are driven in part by the perceived risk of disease progression during avoidable delays. However, it is unclear...
5.
Tierney J, Fisher D, Vale C, Burdett S, Rydzewska L, Rogozinska E, et al.
PLoS Med
. 2021 May;
18(5):e1003629.
PMID: 33956789
Background: The vast majority of systematic reviews are planned retrospectively, once most eligible trials have completed and reported, and are based on aggregate data that can be extracted from publications....
6.
Tierney J, Fisher D, Burdett S, Stewart L, Parmar M
PLoS Med
. 2020 Feb;
17(1):e1003019.
PMID: 32004320
Background: It remains unclear when standard systematic reviews and meta-analyses that rely on published aggregate data (AD) can provide robust clinical conclusions. We aimed to compare the results from a...
7.
8.
Burdett S, Boeve L, Ingleby F, Fisher D, Rydzewska L, Vale C, et al.
Eur Urol
. 2019 Mar;
76(1):115-124.
PMID: 30826218
Background: Many trials are evaluating therapies for men with metastatic hormone-sensitive prostate cancer (mHSPC). Objective: To systematically review trials of prostate radiotherapy. Design, Setting, And Participants: Using a prospective framework...
9.
Navani N, Fisher D, Tierney J, Stephens R, Burdett S
Chest
. 2018 Nov;
155(3):502-509.
PMID: 30391190
Background: Clinical staging of non-small cell lung cancer (NSCLC) helps determine the prognosis and treatment of patients; few data exist on the accuracy of clinical staging and the impact on...
10.
Rydzewska L, Burdett S, Vale C, Parmar M, Tierney J
Eur J Cancer
. 2018 Mar;
94:218-219.
PMID: 29548532
No abstract available.